RSS Feed
Search Ask-Cato.com
Tags
adverse events biologics biosimilar biotech cancer Cato BioVentures Cato Research CDER clinical investigator clinical research clinical trials CMC conference CROs DIA drug development eCTD efficacy FDA funding GlobalSubmit guidance Health Canada IND in vitro diagnostics labeling manufacturing marketing application medical devices NDA NIH nonclinical research oncology Phase 1 Phase 2 postmarketing protocol regulatory affairs safety statistical analysis toxicology transparency venture capital warning letters webinarCategories
- Clinical Trials (52)
- Conferences and Meetings (34)
- eCTD (26)
- FDA (71)
- Guest Posts (5)
- Health Canada (6)
- Industry News (56)
- Project Management (1)
- Publications (7)
- Regulatory Strategy (36)
- Social Media (6)
- Statistics (9)
- Uncategorized (1)
- Venture Capital (10)
- Webinars (24)
Tag Archives: Novartis
DDMAC Sends Warning Letter Over Unbranded Websites
If you judge, investigate. – Seneca I know you just read the title, but let me say it again with some emphasis: DDMAC Sends Warning Letter Over Unbranded Websites. That’s right, a warning letter over websites that contained no “direct” … Continue reading
Posted in FDA, Industry News
Tagged 21 CFR, accelerated approval, advertising, CDER, clinical trials, DDMAC, FDA, first-line treatment, Gleevac, Novartis, off label promotion, oncology, unbranded websites, warning letters
2 Comments
Blockbuster Sales Forecasts for 2010 and 2014
The most reliable way to forecast the future is to try to understand the present. – John Naisbitt Interested in what blockbuster drug sales may be like for the next 4 years? Trying to position your developing therapeutic against the … Continue reading
Posted in Industry News
Tagged Amgen, AstraZeneca, blockbuster drug, forecasts, GSK, Merck, Novartis, Pfizer, Roche, sanofi-aventis
Comments Off
